Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status approved
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII BG3F62OND5
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Type IV hypersensitivity reaction10.01.03.0220.000224%Not Available
Infusion site oedema12.07.05.013; 08.02.05.0120.000280%Not Available
Cerebral disorder17.02.10.0170.000224%Not Available
Infusion site reaction08.02.05.005; 12.07.05.0060.000168%Not Available
Brain cancer metastatic17.20.04.001; 16.30.04.0010.000112%Not Available
Haemorrhage24.07.01.002--Not Available
Fluid intake reduced14.05.10.0010.000336%Not Available
Faecaloma07.01.03.0040.000448%Not Available
Pulmonary mass22.02.07.0040.000336%Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.0040.000112%Not Available
Peripheral sensorimotor neuropathy17.09.03.0090.000246%Not Available
Pneumatosis intestinalis07.11.01.0430.000224%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.0010.000168%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000414%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000504%Not Available
Bloody discharge24.07.01.041; 08.01.03.0390.000168%Not Available
Cancer pain16.32.03.0040.000112%Not Available
Pulseless electrical activity02.03.04.0200.000246%Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.0100.000168%Not Available
Skin oedema23.06.04.0010.000336%Not Available
Bicytopenia01.03.03.0100.000392%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000560%Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.001231%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000224%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000839%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.0270.003268%
Neurological symptom17.02.05.010--Not Available
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene